Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares (KNSA)
NASDAQ
Closed
Oct 7, 2026
Day's Range
74.7052 wk Range
35.20Overview - KNSA - Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares
Key Statistics
Valuation
Enterprise Value
5.39B
P/E (Trailing)
‪76.55‬
P/E (Forward)
‪46.85‬
PEG Ratio
‪2.04‬
Price / Sales (TTM)
‪6.93‬
Price / Book
‪9.03‬
EV / EBITDA
‪52.88‬
Profitability
Gross Margin
‪54.17%‬
Profit Margin
‪9.59%‬
Operating Margin
‪11.16%‬
Return on Assets
‪8.04%‬
Return on Equity
‪14.03%‬
Ownership
Shares Outstanding
77.97M
Float
39.85M
Short % of Shares Outstanding
‪9.69%‬
Held by Insiders
‪3.50%‬
Held by Institutions
‪100.94%‬
Price stats
Beta
‪0.08‬
50-Day Avg
‪77.00‬
200-Day Avg
‪56.21‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
8 analysts
Average price target
‪$ 98.00‬Shariah Compliance
Report Date: Feb 15, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - KNSA - Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares
Peers - KNSA - Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares
Peer Comparison
Compared with companies in Drug Manufacturers - Specialty & Generic listed on NASDAQ.
- KNSANASDAQKiniksa Pharmaceuticals International, plc Class A Ordinary Shares5.83BMarket Cap+49.48%52-week change76.56P/E (Trailing)‪9.59%‬Profit Margin
- NBIXNASDAQNeurocrine Biosciences, Inc.14.55BMarket Cap+2.62%52-week change20.93P/E (Trailing)‪20.91%‬Profit Margin
- AMRXNASDAQAmneal Pharmaceuticals, Inc.7.07BMarket Cap+48.03%52-week change42.29P/E (Trailing)‪5.04%‬Profit Margin
- ALKSNASDAQAlkermes plc7.00BMarket Cap+25.77%52-week change109.87P/E (Trailing)‪3.96%‬Profit Margin
- LNTHNASDAQLantheus Holdings Inc.6.52BMarket Cap+47.28%52-week change23.91P/E (Trailing)‪17.69%‬Profit Margin
- DIODNASDAQDiodes Incorporated4.43BMarket Cap+44.79%52-week change51.08P/E (Trailing)‪5.26%‬Profit Margin
- INDVNASDAQIndivior Pharmaceuticals, Inc.4.21BMarket Cap+36.35%52-week change12.68P/E (Trailing)‪26.74%‬Profit Margin
Profile Summary - KNSA - Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares
About
Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares represents an equity interest in Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company focused on discovering, developing, and commercializing therapies for immune-mediated and inflammatory diseases. The company’s current portfolio…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
